PubRank

Christian Plank

Author PubWeight™ 71.01‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Toll-like receptor expression in human keratinocytes: nuclear factor kappaB controlled gene activation by Staphylococcus aureus is toll-like receptor 2 but not toll-like receptor 4 or platelet activating factor receptor dependent. J Invest Dermatol 2003 1.69
2 Generation of magnetic nonviral gene transfer agents and magnetofection in vitro. Nat Protoc 2007 1.60
3 Labelling of cells with quantum dots. Nanotechnology 2005 1.57
4 A novel transfecting peptide comprising a tetrameric nuclear localization sequence. J Mol Med (Berl) 2003 1.48
5 Insights into the mechanism of magnetofection using PEI-based magnetofectins for gene transfer. J Gene Med 2004 1.48
6 Percutaneous endoscopic gastrostomy in children on peritoneal dialysis. Perit Dial Int 2006 1.47
7 Prevalence of WT1 mutations in a large cohort of patients with steroid-resistant and steroid-sensitive nephrotic syndrome. Kidney Int 2004 1.46
8 Oligomers of the arginine-rich motif of the HIV-1 TAT protein are capable of transferring plasmid DNA into cells. J Biol Chem 2003 1.45
9 Intrauterine growth restriction leads to a dysregulation of Wilms' tumour supressor gene 1 (WT1) and to early podocyte alterations. Nephrol Dial Transplant 2012 1.44
10 Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy. J Control Release 2009 1.42
11 Changes in 11beta-hydroxysteroid dehydrogenase type 2 expression in a low-protein rat model of intrauterine growth restriction. Nephrol Dial Transplant 2010 1.40
12 Magnetofection--a highly efficient tool for antisense oligonucleotide delivery in vitro and in vivo. Mol Ther 2003 1.29
13 Magnetofection potentiates gene delivery to cultured endothelial cells. J Vasc Res 2003 1.20
14 Nonviral vector loaded collagen sponges for sustained gene delivery in vitro and in vivo. J Gene Med 2002 1.15
15 Gene delivery to respiratory epithelial cells by magnetofection. J Gene Med 2004 1.06
16 siRNA delivery by magnetofection. Curr Opin Mol Ther 2008 0.98
17 Inhibition of the tyrosine phosphatase SHP-2 suppresses angiogenesis in vitro and in vivo. J Vasc Res 2007 0.95
18 Application of novel solid lipid nanoparticle (SLN)-gene vector formulations based on a dimeric HIV-1 TAT-peptide in vitro and in vivo. Pharm Res 2004 0.94
19 Aerosolized nanogram quantities of plasmid DNA mediate highly efficient gene delivery to mouse airway epithelium. Mol Ther 2005 0.94
20 Successful withdrawal of steroids in pediatric renal transplant recipients receiving cyclosporine A and mycophenolate mofetil treatment: results after four years. Transplantation 2004 0.92
21 Recent advances in magnetofection and its potential to deliver siRNAs in vitro. Methods Mol Biol 2009 0.92
22 Inhibition of TGF-β signaling and decreased apoptosis in IUGR-associated lung disease in rats. PLoS One 2011 0.91
23 Monomolecular assembly of siRNA and poly(ethylene glycol)-peptide copolymers. Biomacromolecules 2008 0.91
24 The implications of fetal programming of glomerular number and renal function. J Mol Med (Berl) 2009 0.91
25 Therapeutic vaccination with an interleukin-2-interferon-gamma-secreting allogeneic tumor vaccine in patients with progressive castration-resistant prostate cancer: a phase I/II trial. Hum Gene Ther 2009 0.90
26 Mannose receptor-mediated gene delivery into antigen presenting dendritic cells. Somat Cell Mol Genet 2002 0.90
27 A fibrin glue composition as carrier for nucleic acid vectors. Pharm Res 2008 0.90
28 Genuine DNA/polyethylenimine (PEI) complexes improve transfection properties and cell survival. J Drug Target 2004 0.89
29 Neoadjuvant gene delivery of feline granulocyte-macrophage colony-stimulating factor using magnetofection for the treatment of feline fibrosarcomas: a phase I trial. J Gene Med 2008 0.87
30 Gene silencing mediated by magnetic lipospheres tagged with small interfering RNA. Nano Lett 2010 0.87
31 Primary focal segmental glomerulosclerosis--long-term outcome after pediatric renal transplantation. Pediatr Transplant 2005 0.86
32 Effects of nanoparticle coatings on the activity of oncolytic adenovirus-magnetic nanoparticle complexes. Biomaterials 2011 0.85
33 Boosting oncolytic adenovirus potency with magnetic nanoparticles and magnetic force. Mol Pharm 2010 0.85
34 Fetal programming of renal function. Pediatr Nephrol 2011 0.85
35 Silica-iron oxide magnetic nanoparticles modified for gene delivery: a search for optimum and quantitative criteria. Pharm Res 2012 0.84
36 Alpha-secretase inhibition reduces human glioblastoma stem cell growth in vitro and in vivo by inhibiting Notch. Neuro Oncol 2012 0.84
37 In vivo analysis of retroviral gene transfer to chondrocytes within collagen scaffolds for the treatment of osteochondral defects. Biomaterials 2007 0.83
38 Magnetofection: the use of magnetic nanoparticles for nucleic acid delivery. Cold Spring Harb Protoc 2009 0.83
39 Fetal programming of gene expression in growth-restricted rats depends on the cause of low birth weight. Endocrinology 2011 0.83
40 Hydrochlorothiazide in CLDN16 mutation. Nephrol Dial Transplant 2006 0.83
41 Magselectofection: an integrated method of nanomagnetic separation and genetic modification of target cells. Blood 2011 0.83
42 Early and late postnatal myocardial and vascular changes in a protein restriction rat model of intrauterine growth restriction. PLoS One 2011 0.83
43 Low nephron number--a new cardiovascular risk factor in children? Pediatr Nephrol 2004 0.83
44 Pediatric renal transplantation with mycophenolate mofetil-based immunosuppression without induction: results after three years. Transplantation 2003 0.83
45 Nucleic acid delivery to magnetically-labeled cells in a 2D array and at the luminal surface of cell culture tube and their detection by MRI. J Biomed Nanotechnol 2009 0.81
46 A strategy to establish a gene-activated matrix on titanium using gene vectors protected in a polylactide coating. Biomaterials 2011 0.81
47 The influence of the stable expression of BMP2 in fibrin clots on the remodelling and repair of osteochondral defects. Biomaterials 2009 0.81
48 Hypertonic-hyperoncotic solutions improve cardiac function in children after open-heart surgery. Pediatrics 2006 0.80
49 Nanomagnetic activation as a way to control the efficacy of nucleic acid delivery. Pharm Res 2014 0.80
50 Immunostimulation of bronchoalveolar lavage cells from recurrent airway obstruction-affected horses by different CpG-classes bound to gelatin nanoparticles. Vet Immunol Immunopathol 2011 0.80
51 Non-viral VEGF(165) gene therapy--magnetofection of acoustically active magnetic lipospheres ('magnetobubbles') increases tissue survival in an oversized skin flap model. J Cell Mol Med 2008 0.80
52 Induction and coexpression of latent transforming growth factor beta-binding protein-1 and fibrillin-1 in experimental glomerulonephritis. Nephron Exp Nephrol 2005 0.79
53 Aerosol gene delivery to the murine lung is mouse strain dependent. J Mol Med (Berl) 2006 0.79
54 Effects of statins on nitric oxide/cGMP signaling in human umbilical vein endothelial cells. Pharmacol Rep 2010 0.79
55 Five-year outcome in pediatric patients with mycophenolate mofetil-based renal transplantation. Transplantation 2007 0.79
56 Bioactivation of dermal scaffolds with a non-viral copolymer-protected gene vector. Biomaterials 2010 0.79
57 Nanomedicine: Silence the target. Nat Nanotechnol 2009 0.79
58 A nebulized gelatin nanoparticle-based CpG formulation is effective in immunotherapy of allergic horses. Pharm Res 2012 0.78
59 Pharmacokinetics and immunodynamics of basiliximab in pediatric renal transplant recipients on mycophenolate mofetil comedication. Transplantation 2008 0.78
60 Early postnatal hyperalimentation impairs renal function via SOCS-3 mediated renal postreceptor leptin resistance. Endocrinology 2012 0.78
61 Biophysical characterization of copolymer-protected gene vectors. Biomacromolecules 2010 0.78
62 Liposomal magnetofection. Methods Mol Biol 2010 0.78
63 Targeted magnetic liposomes loaded with doxorubicin. Methods Mol Biol 2010 0.78
64 Site directed vascular gene delivery in vivo by ultrasonic destruction of magnetic nanoparticle coated microbubbles. Nanomedicine 2012 0.77
65 Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids. Transplantation 2008 0.77
66 End-stage renal failure as manifestation of adolescent cystinosis. Eur J Pediatr 2004 0.77
67 Magnetically guided lentiviral-mediated transduction of airway epithelial cells. J Gene Med 2010 0.77
68 Effects of adrenomedullin on the glomerular adrenomedullin system in a rat model of anti-thy1 glomerulonephritis. Nephron Exp Nephrol 2010 0.76
69 Stability analysis of chemically modified mRNA using micropattern-based single-cell arrays. Lab Chip 2015 0.76
70 Magnetic nanoparticles for biomedical applications. Pharm Res 2012 0.76
71 Hypergonadotropic hypogonadism and renal failure due to WT1 mutation. Nephrol Dial Transplant 2006 0.76
72 Developmental regulation of inflammatory cytokine-mediated Stat3 signaling: the missing link between intrauterine growth restriction and pulmonary dysfunction? J Mol Med (Berl) 2012 0.76
73 Efficient and stable gene transfer of growth factors into chondrogenic cells and primary articular chondrocytes using a VSV.G pseudotyped retroviral vector. Biomaterials 2008 0.76
74 Magnetic and acoustically active microbubbles loaded with nucleic acids for gene delivery. Methods Mol Biol 2013 0.76
75 Continuous flow generation of magnetoliposomes in a low-cost portable microfluidic platform. Lab Chip 2014 0.76
76 Is tacrolimus for childhood steroid-dependent nephrotic syndrome better than ciclosporin A? Nephrol Dial Transplant 2006 0.76
77 Optimizing adenoviral transduction of endothelial cells under flow conditions. Pharm Res 2011 0.75
78 Magnetic nanoparticle and magnetic field assisted siRNA delivery in vitro. Methods Mol Biol 2015 0.75
79 Thyroid hormone (T3)-modification of polyethyleneglycol (PEG)-polyethyleneimine (PEI) graft copolymers for improved gene delivery to hepatocytes. Biomaterials 2006 0.75
80 Altered leptin secretion in hyperinsulinemic mice under hypoxic conditions. Regul Pept 2008 0.75
81 The use of non-viral gene vectors for bioactive poly-(D,L-lactide) implant surfaces in bone tissue engineering. Eur Cell Mater 2012 0.75
82 Autosomal recessive polycystic kidney disease: improvement of renal function. Eur J Pediatr 2003 0.75
83 Persistent changes within the intrinsic kidney-associated NPY system and tubular function by litter size reduction. Nephrol Dial Transplant 2011 0.75
84 Pediatric renal allograft transplantation does not normalize the increased cortisol/cortisone ratios of chronic renal failure. Eur J Endocrinol 2006 0.75
85 Engineering magnetic nanoparticles and formulations for gene delivery. J Control Release 2010 0.75
86 [Intrauterine growth restriction and renal function--a long-term problem?]. Gynakol Geburtshilfliche Rundsch 2009 0.75
87 Mycophenolate mofetil introduction stabilizes and subsequent cyclosporine A reduction slightly improves kidney function in pediatric renal transplant patients: a retrospective analysis. Pediatr Transplant 2006 0.75